Physician
Oncology
Dr. John V. Heymach, MD
|
|
Give Review
John V. Heymach, MD works in the field of Oncology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. John Heymach is also a published doctor. He has 101 publication published. The most recent publication is: MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. John Heymach is registered with Medicare and accepts Medicare payments.
Publications
- Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell Carcinoma.
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
- Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in l...
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
- KDR AMPLIFICATION IS ASSOCIATED WITH VEGF-INDUCED ACTIVATION OF mTOR AND INVASION PATHWAYS BUT DOES NOT PREDICT CLINICAL BENEFIT TO THE VEGFR TKI VANDETANIB.
- Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
- Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced Neuroendocrine tumours.
- Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung Cancer.
- drexplorer: A tool to explore dose-response relationships and drug-drug interactions.
- Intratumor heterogeneity in localized lung adenoCarcinomas delineated by multiregion sequencing.
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
- Propensity Score-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy.
- A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma.
- A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small-Cell Lung Cancer.
- VEGF/VEGFR-2 upregulates EZH2 expression in lung adenoCarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
- Therapeutic delivery of miR-200c enhances radiosensitivity in lung Cancer.
- An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
- About CD45-/CD31+/CD105+ Circulating Cells in Patients with Gynecologic Malignancies--Letter.
- Tumor endothelial markers define novel subsets of Cancer-specific circulating endothelial cells associated with antitumor efficacy.
- Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma.
- Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0...
- Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung Cancer.
- HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell Carcinoma cells.
- Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial.
- Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small-Cell Lung Cancer after Neoadjuvant C...
- Modulation of c-Met signaling and cellular sensitivity to radiation: Potential implications for therapy.
- Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.
- Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenoCarcinoma.
- Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
- C-Met Inhibitor MK-8003 Radiosensitizes c-Met-Expressing Non-Small-Cell Lung Cancer Cells With Radiation-Induced c-Met-Expression.
- Global evaluation of Eph receptors and ephrins in lung adenoCarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell Cancer: a retrospective analysis of phas...
- Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine Tumors: current data and clinical outlook.
- Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis.
- Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications.
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?
- Targeted therapies for lung Cancer: clinical experience and novel agents.
- Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube Cancer.
- Effect of low-fat diets on plasma levels of NF-?B-regulated inflammatory cytokines and angiogenic factors in men with prostate Cancer.
- Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients.
- Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy.
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept.
- Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer.
- DNA repair biomarker profiling of head and neck Cancer: Ku80 expression predicts locoregional failure and death following radiotherapy.
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenoCarcinoma.
- miR-200 Inhibits lung adenoCarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
- Proteomic profiling identifies pathways dysregulated in non-small cell lung Cancer and an inverse association of AMPK and adhesion pathways with recurrence.
- Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell Cancer.
- A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhi...
- A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and Oral celecoxib in patients with metastatic melanoma.
- Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung Cancer patients treated with pazo...
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with...
- Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung Cancer.
- Reciprocal regulation of c-Src and STAT3 in non-small cell lung Cancer.
- HIF2alpha cooperates with RAS to promote Lung tumorigenesis in mice.
- Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor r...
- Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell Carcinoma.
- Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung Cancer.
- Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses.
- Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast Cancer xenografts that overexpress HER2.
- Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung Cancer.
- Lung Cancer.
- Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR...
- Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib.
- The tyrosine kinase inhibitor cediranib for non-small cell lung Cancer and other thoracic malignancies.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
- Second-line treatment of advanced non-small cell lung Cancer.
- PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung Cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
- Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
- Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung Cancer.
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung Cancer.
- Novel agents in the treatment of lung Cancer: Fourth Cambridge Conference.
- The convergent development of molecular-targeted drugs for Cancer treatment and prevention.
- Endothelial progenitor cells contribute to accelerated Liver regeneration.
- Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
- Vascular endothelial growth factor accelerates compensatory Lung growth after unilateral pneumonectomy.
- Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell Lung can...
- Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian Cancer.
- Vascular endothelial growth factor (VEGF) pathway.
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung Cancer.
- Angiogenesis inhibitors for lung Cancer: clinical developments and future directions.
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine Tumors.
- Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung Cancer.
- Summary statement: novel agents in the treatment of lung Cancer: advances in epidermal growth factor receptor-targeted agents.
- Emerging antiangiogenic agents in lung Cancer.
- Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
- Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells:...
- Pharmacodynamic analysis of target inhibition and endothelial cell death in Tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or S...
- Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
- Farnesyl transferase inhibitors for patients with lung Cancer.
- Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.
- Genes suppressed by DNA methylation in non-small cell lung Cancer reveal the epigenetics of epithelial-mesenchymal transition.
- MYB-fusions and other potential actionable targets in adenoid cystic Carcinoma.
Schools
Stanford Univ Sch Of Med
Med Onc
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Stanford University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1417056565 | |
| NPPES Provider LastName | HEYMACH | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 229.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 18.0 | |
| Percent Opioid Claims | 7.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1417056565 |
| Last Name Of The Provider | HEYMACH |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
Dr. Robert J. Amato, DO |
|
|
Dr. Sumit K. Subudhi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William N. William Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nishin A. Bhadkamkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Fisch, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert F. Todd, MD |
|
|
Dr. Eric H. Bernicker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Verena M. Hug, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad Pecot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mohamed Haq, MB
This Doctor is OpenDoctor Recommended.
|